The NQO1 rs1800566 Polymorphism and Risk of Bladder Cancer: Evidence from 6,169 Subjects

Objective: The NAD(P)H:quinone oxidoreductase 1 (NQO1) rs1800566 polymorphism, leading to prolinetoserineamino-acid and enzyme activity changes, has been implicated in bladder cancer risk, but individuallypublished studies showed inconsistent results. We therefore here conducted a meta-analysis to summarize thepossible association.
Methods: A systematic literature search up to August 27, 2012 was carried out in PubMed,EMBASE and Wanfang databases, and the references of retrieved articles were screened. Crude odds ratios (ORs)with 95% confidence intervals (CIs) were analyzed for homozygote contrast (TT vs. CC), additive model (T vs.C), dominant model (TT+CT vs. CC), and recessive model (TT vs. CC+CT) to assess the association using fixedorrandom-effect models.
Results: We identified 12 case-control studies including 3,041 cases and 3,128 controlsfor the present meta-analysis. Significant association between NQO1 rs1800566 genetic polymorphism and riskof bladder cancer was observed in the additive model (OR = 1.15, 95% CI = 1.01-1.30, p = 0.030). Moreover, inthe subgroup analysis stratified by ethnicity, significant associations were observed in Asians (OR = 1.26, 95%CI = 1.08–1.47, p = 0.003 for T vs. C; OR = 1.68, 95% CI = 1.21-2.32, p = 0.002 for TT vs. CC; OR = 1.50, 95%CI = 1.13-1.98, p = 0.005 for TT vs. CT+CC) but not in Caucasians.
Conclusions: The results suggest that NQO1rs1800566 genetic polymorphism may contribute to bladder cancer development, especially in Asians.